A unit of American International Group Inc. filed suit against a Tyco International Ltd. subsidiary on Wednesday over an allegedly unfair offer Tyco has made to buy back $5.6 billion in Tyco bonds in preparation for its liquidation.
A group of pharmaceutical wholesalers has lost an appeal brought against Wyeth-Ayerst Laboratories over claims the drug maker hiked up the price of its hormone medication while keeping its competitor out of the lucrative market.
A federal court ruled Friday that generic drug companies Teva Pharmaceutical Industries Ltd. and Dr. Reddy’s Laboratories Ltd. infringed Eisai Co. Ltd.’s patent on the ulcer medicine Aciphex.
Now that Bristol-Myers Squibb Co. has tentatively settled criminal antitrust charges with the U.S. Department of Justice, it will wait to see whether the Federal Trade Commission or states take civil action against it over a failed Plavix patent agreement.
The Food and Drug Administration had its power to regulate imported drugs clarified Thursday when the Seventh Circuit Court of Appeals upheld its 2003 seizure and condemnation of drugs, imported by Genendo Pharmaceuticals, that were improperly packaged and labeled.
A subsidiary of artificial heart valve maker Edwards Lifesciences Corp. has reached across the Atlantic to stick an Irvine, Calif.-based rival with an infringement suit over transcatheter technology.
In a win for Johnson & Johnson, a U.S. appeals court has upheld a ban on the sale of a cheap version of the pharmaceutical giant’s antipsychotic drug Risperdal for the life of its key patent.
A bipartisan amendment added to a bill renewing drug user fees that passed the U.S. Senate Wednesday would alter the citizen petition process for Abbreviated New Drug Applications, making it harder for brand-name drug makers to use "frivolous" petitions as a way to delay generic drugs, advocates say.
U.S. regulators have recently joined forces to crack down on Medicare fraud across the country, an effort that has already netted 42 arrests of individuals allegedly connected to health care fraud schemes, the U.S. Attorney’s Office for the Southern District of Florida said Thursday.
Allergan Inc. disclosed Wednesday that it has sued generic pharmaceutical company Exela PharmSci Inc. for allegedly infringing its patent for an eye drop medication used to treat glaucoma.
With proceedings at a virtual standstill, a group of attorneys representing asbestos victims has asked the Manhattan bankruptcy court to intervene in the case of a defunct Pfizer unit and appoint a Chapter 11 Trustee.
Upholding a ruling that a patent over a children’s educational toy was obvious and invalid, the Federal Circuit on Wednesday pronounced the end of a lawsuit between rival toymakers LeapFrog Enterprises Inc. and Fisher-Price Inc. that had dragged on for years.
A lawsuit lodged in Mannheim, Germany has alleged that some of Boston Scientific Corp.’s balloon catheter products infringe a German patent asserted by SciCo Tec GmbH.
The company that makes the narcotic pain killer Oxycontin and three former executives pled guilty Thursday to charges of misbranding the drug and agreed to fork over more than $700 million in payments to the government.
A judge has ruled that genetic test maker Digene Corp. has suffered no irreparable harm by a rival’s sales of its patented products, denying the company’s request for a ban.
Settlement talks have broken off between Biovail Corp. Chair Eugene Melnyk and the Ontario Securities Commission in its case accusing him of failing to report trades of the company’s stock placed in several trusts.
ExxonMobil Corp. claims that it is the latest victim of a habitual Internet domain name trademark infringer, which allegedly is profiting from the oil giant’s XOM trademark and confusing its employees by running a Web site with a domain name similar to the company’s pension plan site.
Cardinal Health Inc. will pay $600 million to settle a massive class action lawsuit that alleged the company had misled investors by overstating earnings.
The former head of China’s State Food and Drug Administration will go on trial Tuesday of next week for allegedly taking bribes to approve untested medicines and loosen quality checks in the country.
While developing countries continue to break AIDS drug patents, former President Bill Clinton has negotiated a new deal with two pharmaceutical giants in an attempt to provide poor nations with cheaper versions of drugs needed to combat the deadly disease.